PE20212157A1 - PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM - Google Patents

PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM

Info

Publication number
PE20212157A1
PE20212157A1 PE2021001288A PE2021001288A PE20212157A1 PE 20212157 A1 PE20212157 A1 PE 20212157A1 PE 2021001288 A PE2021001288 A PE 2021001288A PE 2021001288 A PE2021001288 A PE 2021001288A PE 20212157 A1 PE20212157 A1 PE 20212157A1
Authority
PE
Peru
Prior art keywords
meloxicam
migraine
rizatriptan
pain
administered
Prior art date
Application number
PE2021001288A
Other languages
Spanish (es)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of PE20212157A1 publication Critical patent/PE20212157A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

SSe describe en la presente, composiciones que comprenden un NSAID como meloxicam y/o rizatriptan en combinacion con una ciclodextrina y/o un carbonato o un bicarbonato. Estas composiciones pueden ser oralmente administradas, por ejemplo, para mejorar la biodisponibilidad o farmacocineticas del NSAID para el tratamiento de dolor como migrana, artritis, y otras afecciones. Tambien se describen metodos para tratar el dolor, como migrana, que comprenden administrar meloxicam y rizatriptan a un ser humano que sufre de dolor, como migrana. Para la migrana, estos metodos pueden ser particularmente utiles cuando el meloxicam y el rizatriptan son administrados mientras el ser humano esta sufriendo de un ataque agudo de dolor de migrana o aura de migrana. En algunas modalidades, la combinacion de meloxicam y rizatriptan pueden ser administrados en una forma que resulta en una Tmax de meloxicam de 3 horas o menos.Described herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions can be administered orally, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed are methods of treating migraine-like pain, comprising administering meloxicam and rizatriptan to a human suffering from migraine-like pain. For migraine, these methods may be particularly useful when meloxicam and rizatriptan are administered while the human is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan can be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

PE2021001288A 2019-02-06 2020-02-06 PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM PE20212157A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962802198P 2019-02-06 2019-02-06
US201962803756P 2019-02-11 2019-02-11
US201962835613P 2019-04-18 2019-04-18
US201962846311P 2019-05-10 2019-05-10
US201962860705P 2019-06-12 2019-06-12
US201962895956P 2019-09-04 2019-09-04
US201962895933P 2019-09-04 2019-09-04
US201962955905P 2019-12-31 2019-12-31
PCT/US2020/017046 WO2020163620A1 (en) 2019-02-06 2020-02-06 Pharmaceutical compositions comprising meloxicam

Publications (1)

Publication Number Publication Date
PE20212157A1 true PE20212157A1 (en) 2021-11-09

Family

ID=71947112

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001288A PE20212157A1 (en) 2019-02-06 2020-02-06 PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM

Country Status (17)

Country Link
EP (1) EP3920909A4 (en)
JP (3) JP7237386B2 (en)
KR (1) KR20210118880A (en)
CN (1) CN113423397A (en)
AU (2) AU2020218253B2 (en)
BR (1) BR112021015467A2 (en)
CA (2) CA3213549A1 (en)
CL (1) CL2021002070A1 (en)
CO (1) CO2021010380A2 (en)
CR (1) CR20210420A (en)
EC (1) ECSP21060962A (en)
IL (1) IL285389A (en)
MA (1) MA54904A (en)
MX (1) MX2021009435A (en)
PE (1) PE20212157A1 (en)
SG (1) SG11202107926XA (en)
WO (1) WO2020163620A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024502041A (en) * 2020-12-31 2024-01-17 アクスサム セラピューティクス インコーポレイテッド Pharmaceutical compositions containing meloxicam

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1126841B1 (en) * 1998-11-02 2004-12-15 Merck & Co., Inc. Combinations of a 5ht1b/1d agonist and a selective cox-2 inhibitor for the treatment of migraine
US20040214861A1 (en) * 2003-03-28 2004-10-28 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20090068262A1 (en) * 2007-04-04 2009-03-12 Ilan Zalit Rapid dissolution of combination products
ES2769949T3 (en) * 2009-05-13 2020-06-29 Cydex Pharmaceuticals Inc Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of preparing and using them
US9821075B2 (en) * 2015-02-10 2017-11-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
AU2016218992C1 (en) * 2015-02-10 2019-09-26 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
SI3256138T1 (en) * 2015-11-25 2022-07-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
CN109952314A (en) * 2016-09-23 2019-06-28 泰瓦制药国际有限公司 Treat intractable migraine
PT3565550T (en) * 2017-01-04 2021-01-20 Axsome Therapeutics Inc Pharmaceutical compositions comprising meloxicam
US10471014B2 (en) * 2017-01-04 2019-11-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
CN110612103B (en) * 2017-05-10 2023-08-22 艾克萨姆治疗公司 Pharmaceutical composition comprising meloxicam

Also Published As

Publication number Publication date
MX2021009435A (en) 2021-09-10
EP3920909A4 (en) 2022-11-30
MA54904A (en) 2021-12-15
WO2020163620A1 (en) 2020-08-13
ECSP21060962A (en) 2021-11-30
CO2021010380A2 (en) 2021-09-30
EP3920909A1 (en) 2021-12-15
JP2023062144A (en) 2023-05-02
JP2022519670A (en) 2022-03-24
AU2020218253A1 (en) 2021-08-12
CA3128940A1 (en) 2020-08-13
SG11202107926XA (en) 2021-08-30
CR20210420A (en) 2021-12-22
JP2024026732A (en) 2024-02-28
AU2020218253B2 (en) 2023-02-23
JP7237386B2 (en) 2023-03-13
IL285389A (en) 2021-09-30
CN113423397A (en) 2021-09-21
BR112021015467A2 (en) 2021-10-05
JP7420990B2 (en) 2024-01-23
AU2023202545A1 (en) 2023-05-18
CA3128940C (en) 2023-11-07
KR20210118880A (en) 2021-10-01
CL2021002070A1 (en) 2022-04-01
CA3213549A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
CL2018001420A1 (en) Treatment of cognitive disorders with (r) -7-chloro-n- (quinuclidin-3-yl) benzo [b] thiophene-2-carboxamide and pharmaceutically acceptable salts thereof. (divisional application 201701853)
CL2020002512A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors.
CO6531463A2 (en) COMBINATIONS OF A PI3K INHIBITOR AND A MEK INHIBITOR
EA200701195A1 (en) CONTAINING CEFALOSPORIN COMPOSITIONS WITH NANOPARTICLES AND WITH CONTROLLED DELIVERY
EA201691454A1 (en) COMPOSITIONS OF PRIDOPIDININE MODIFIED SHIPPING
CO6341486A2 (en) TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS
MX2022003072A (en) Use of pridopidine for treating functional decline.
CL2018001677A1 (en) Treatment of fabry disease in patients not treated and previously treated with ert
CO2018003224A2 (en) Modified release amino acid formulations administered orally
BR112015018360A2 (en) Combination therapy for the treatment of nosocomial pneumonia
CL2019000190A1 (en) Treatment and prevention of sleep disorders.
MX2023009631A (en) Methods of treating seizure disorders and prader-willi syndrome.
ECSP21060962A (en) PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM
ZA202006072B (en) Ret inhibitor for use in treating cancer having a ret alteration
MX2021002322A (en) Novel methods.
CO2020004034A2 (en) Methods for the treatment of muscular dystrophy
CO2020015377A2 (en) Modulators of apol1 expression
BR112015032284A2 (en) medical device comprising collagen-vi
BR122021012549B8 (en) ORAL MELATONIN DISSOLUTION COMPOSITION WITH ACIDIFYING AGENT THAT MAKES MELATONIN SOLUBLE IN SALIVA
BR112014030777A2 (en) Method and composition to relieve tumor symptoms
CL2020000859A1 (en) Gluconic acid derivatives to be used in the treatment and / or prevention of microbial infections.
MX2018015208A (en) Andrographolide treats progressive forms of multiple sclerosis.
MX2021003651A (en) Formulation comprising ozonised oil in the treatment of a tumour.
AR114306A1 (en) TREATMENT AND PREVENTION OF SLEEP DISORDERS
BR112015015938A2 (en) use of phenylephrine and acetaminophen hydrochloride, drug, method of treatment of upper respiratory tract mucosal congestion in an adult human